Syntegon posts record year in 2025 and aims for further growth

• Revenue increased by 10% to EUR 1.75 billion vs. prior year, reaching a new record. Pharma sales up by 22%.
• Order intake improved to EUR 1.86 billion, flagging continued growth
• Strong EBITDA increase by 27% to EUR 282 million, with EBITDA margin rising to 16.1%, up 210 bps
• Free cash flow up by 51% to EUR 196 million, exceeding the high prior-year level
• Position as strategic lifecycle partner for pharma, biotech, and food industries significantly strengthened
• Outlook 2026: further growth and improved results targeted

Stuttgart (Germany), April 16, 2026 – Syntegon, a leading strategic lifecycle partner to the global pharmaceutical, biotech, and food industries, today announced record results for fiscal year 2025. The strong performance was driven by the successful execution of its customer-focused growth strategy in structurally growing markets.

In 2025, Syntegon increased revenue by 10% to EUR 1.75 billion, while order intake reached EUR 1.86 billion, providing strong visibility into 2026. The strong revenue performance led to significant improvements in EBITDA and cash flow. EBITDA rose by 27% to EUR 282 million, corresponding to an EBITDA margin of 16.1%, an increase of 210 basis points compared to the prior year. Margin expansion was driven by higher volumes in attractive-margin segments, continued cost discipline, operational excellence, and improved project performance. The rebalancing of the company’s global manufacturing footprint, the establishment of an engineering hub in India, and sustained productivity improvements across facilities have additionally structurally supported margin expansion. Free cash flow increased by 51% to EUR 196 million, exceeding an already strong prior-year level. This performance was supported by robust EBITDA growth, a lean capital expenditure model, and disciplined working capital management.

In 2025, Syntegon made targeted investments in capacity expansion, innovation, and modern working environments. The company established a new Business Excellence Center in Stuttgart and significantly expanded its footprint, including the opening of a new Pharma Solid factory in Fellbach, Germany. In parallel, Syntegon further strengthened its R&D pipeline, allocating EUR 56 million to the development of next-generation line solutions. These investments position the company to drive sustainable growth in the years ahead.

Syntegon’s Pharma business sustained strong growth momentum, with sales increasing by 22% versus the prior year. The company operates in structurally growing markets, driven by ongoing biotech innovation and an expanding biologics pipeline, particularly in injectable therapies. At the same time, increasingly stringent regulatory requirements are fueling demand for integrated, technologically advanced solutions. With the acquisition of Telstar, Syntegon strategically expanded its end-to-end pharmaceutical line solution portfolio and, in the first year of integration, delivered results ahead of plan.

The Food business benefited from rapid customer adoption of the company’s recently launched SVX product platform, recognized for its benchmark-setting speed, flexibility, and sustainability performance.

Customers’ continued focus on improving operational efficiency is driving demand for performance upgrades of existing lines, as well as for advanced service solutions. Against this background, the service business continued its solid growth trajectory.

2025 marked an important milestone in Syntegon’s transformation, significantly strengthening its role as a strategic lifecycle partner. Through a series of major innovations, Syntegon further expanded its global market leadership in 2025. A key highlight was the launch of SynTiso, the world's first gloveless high-speed filling line for liquid pharmaceuticals. This breakthrough solution sets new standards in eliminating contamination risks and enhancing efficiency in pharmaceutical production. SynTiso generated significant market interest and initial orders from major pharmaceutical companies.

Sustainability remains a core pillar of Syntegon’s value creation strategy. In 2025, the company was awarded the EcoVadis Platinum Medal, recognizing its strong performance and placing Syntegon among the world’s leading companies in sustainability performance.

With leading market positions, a strong global customer base, the industry’s largest installed base, and breakthrough technologies, Syntegon is well positioned for its next phase of growth and margin expansion. The company aims to gain further market share in mission-critical end markets that are largely resilient to economic fluctuations. A key focus will be expansion in the United States. In addition, the company plans to systematically leverage the service potential of the world’s largest installed system base. With its Business Plan 2030, Syntegon has a clear roadmap to further strengthen its innovation leadership, scale its service business, and execute the next phase of operational excellence initiatives.